|
1
|
Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.
|
Mol Ther
|
2014
|
1.06
|
|
2
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
Mol Ther
|
2014
|
0.89
|
|
3
|
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.
|
Cytotherapy
|
2014
|
0.85
|
|
4
|
The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.
|
Cytotherapy
|
2014
|
0.81
|
|
5
|
Quantitative activation suppression assay to evaluate human bone marrow-derived mesenchymal stromal cell potency.
|
Cytotherapy
|
2015
|
0.80
|
|
6
|
Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.
|
Bone Marrow Transplant
|
2014
|
0.75
|